Notably, combining NSC48160 with the SLC7A11 inhibitor HG106 achieved synergistic tumor suppression, suggesting a paradigm for co‐targeting oncogenic signaling and ferroptosis vulnerability. The gene discussed is SLC7A11; the disease is neoplasm.